As patients navigate the intersection of cardiovascular, mental, and women's health needs, staying current with medication label updates is no longer optional—it's a critical part of safe care ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

Researchers have found in a new study among patients under 65 years treated with NOACs for nonvalvular atrial fibrillation, ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during 3-month trial period. HealthDay News — The risk for clinically relevant bleeding is significantly ...

In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Why it matters: Apixaban is metabolized mainly by CYP3A4 and transported by P-gp, making it vulnerable to interactions that can increase bleeding or reduce effectiveness. Real-world danger: A patient ...

But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...

Older adults with venous thromboembolism (VTE) reported fewer blood clot complications while using apixaban compared to other ...

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...